Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Stage I Breast Cancer AJCC v7: early-phase trial registry

1 of 8 indexed Stage I Breast Cancer AJCC v7 trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

8 US clinical trials · 1 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Stage I Breast Cancer AJCC v7: 8 US clinical trials tracked, 1 recruiting.

Stage I Breast Cancer AJCC v7 is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 5 of these trials.

Enrollment posture brief

Registry condition stage-i-breast-cancer-ajcc-v7

OPEN 1 | RECR 13% | LATE 1 | EARLY 5 | RANK #2176 | SPON 5

Nearest open-share peer: Acute Respiratory Infection (13% recruiting · 8 trials)

Activity, Motor75%Achalasia50%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%Stage I Breast Cancer AJ (th…13%
Open-enrollment share among volume-matched conditions near Stage I Breast Cancer AJCC v7

Stage I Breast Cancer AJCC v7 lists 1 open slots (13% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Stage I Breast Cancer AJCC v7 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Stage I Breast Cancer AJCC v7 is recruiting below its size-band peers.

    1 of 8 indexed trials (12.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Stage I Breast Cancer AJCC v7 research.

    M.D. Anderson Cancer Center accounts for 5 of 8 trials (62.5%). 3 distinct sponsors appear on at least one study for this condition label.

  3. Typical Stage I Breast Cancer AJCC v7 enrolment sits around 200 participants.

    Median target enrolment is 200 among the 8 trials that report a genuine target (sentinel values excluded). 2 of those (25%) plan for fewer than 100 participants.

  4. Stage I Breast Cancer AJCC v7 research is mostly interventional.

    8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 24Phase 31

Open and recent trials

8 total, page 1 of 1

RECRUITING NA 120 participants

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

M.D. Anderson Cancer Center

NCT02945579

ACTIVE NOT RECRUITING Phase 3 1,155 participants

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

National Cancer Institute (NCI)

NCT02954874

ACTIVE NOT RECRUITING Phase 2 805 participants

Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer

M.D. Anderson Cancer Center

NCT02912312

ACTIVE NOT RECRUITING NA 798 participants

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative

M.D. Anderson Cancer Center

NCT02276443

ACTIVE NOT RECRUITING Phase 2 200 participants

Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer

M.D. Anderson Cancer Center

NCT01245712

ACTIVE NOT RECRUITING Phase 2 111 participants

Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment

M.D. Anderson Cancer Center

NCT02754752

ACTIVE NOT RECRUITING Phase 1 32 participants

Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery

National Cancer Institute (NCI)

NCT03317405

COMPLETED Phase 2 20 participants

Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery

University of Nebraska

NCT02654119

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 4
Phase 3 1

Named interventions

Most-linked intervention names on Stage I Breast Cancer AJCC v7 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Laboratory Biomarker Analysis Other
6 trials
Quality-of-Life Assessment Other
5 trials
Questionnaire Administration Other
4 trials
Electroacupuncture Therapy Procedure
1 trials
Lymph Node Biopsy Procedure
1 trials
Ultrasonography Procedure
1 trials
Placebo Administration Other
1 trials
Endoxifen Hydrochloride Drug
1 trials

US sites by state

Facility locations filed on Stage I Breast Cancer AJCC v7 trials. A trial with sites in several states counts in each.

Texas 5 trials
California 3 trials
Arizona 3 trials
New Jersey 2 trials
Florida 2 trials
Pennsylvania 1 trials
Ohio 1 trials
New York 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Stage I Breast Cancer AJCC v7 page

8 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage I Breast Cancer AJCC v7 condition card totals 8 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.